Nan Fung Life Sciences
VC Fund
San Francisco, United States
Nan Fung Life Sciences is a VC fund in San Francisco focused on Biotechnology and Health Care. Nan Fung Life Sciences are a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. Our team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. Through direct investments via Pivotal bioVenturePartners US and Pivotal bioVenture Partners China as well as fund investments, we cover the full spectrum of the life sciences industry including therapeutics, medical devices and diagnostics and across all development stages.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Nan Fung Life Sciences invests in
Stages Nan Fung Life Sciences invests in
Countries Nan Fung Life Sciences invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Investment Focus
Industry
- Biotechnology 14 (52%)
- Health Care 13 (48%)
- Medical 6 (22%)
- Pharmaceutical 6 (22%)
- Life Science 5 (19%)
Stage
- Series B 7 (26%)
- Series A 5 (19%)
- Series C 5 (19%)
- Seed 3 (11%)
- Funding Round 2 (7%)
Country
- United States 12 (44%)
- China 4 (15%)
- Iceland 1 (4%)
- Hong Kong 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Peter Bisgaard
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Peter Bisgaard
Managing Director
|
Managing Director | Total investments: 19 | Find email | |
Vincent Cheung
Founder, Managing Partner
|
Founder, Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Editact
|
Editact specializes in the development of novel gene treatments for Alzheimer's disease. It focuses on unmet clinical requirements in familial Alzheimer's disease (FAD) and is developing "one-to-many" gene editing therapeutics. | Seed / Jul 21, 2025 | |
Heranova Lifesciences
|
Hekaiwei is a provider of innovative solutions for women's health. | $3.5M / Seed / Dec 28, 2023 | |
DermBiont
|
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes(fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California. | $28M / Series A / Dec 21, 2021 | |
Ablaze Pharmaceuticals
|
Ablaze Pharma is a clinical stage bio-pharmaceutical company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients. | $75M / Series A / Nov 29, 2021 | |
Fountain Therapeutics
|
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases.Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of agingthat re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics. | $15M / Series A / Nov 18, 2021 | |
Engrail Therapeutics
|
Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverageour flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. | $32M / Series A / Aug 03, 2021 | |
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M / Series C / May 04, 2021 | |
Arctic Vision
|
Arctic Vision is a China-based clinical-stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The Company's vision is to address ophthalmology's unmet needs through innovative therapies in China, Asia, and globally. Arctic Vision is established by top-tier life sciences investors and led by an eliteteam of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. | $100M / Series B / Mar 09, 2021 | |
Encodia
|
Encodia provides in-depth information on cellular processes to enable personalized medicine.Our technology reverse translates peptide sequence information into a DNA library. This means scientists can scale their research more easily to accelerate novel approaches to our most challenging diseases.Encodia was established on January 1, 2015 inSan Diego, California. | $75M / Series C / Jan 27, 2021 | |
Visen Pharmaceuticals
|
Visen Pharmaceuticals is a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China. | $150M / Series B / Jan 08, 2021 | |
| See all 27 investments → | |||
Co-Investors
Vivo Capital
5 deals together
HBM Healthcare Investments
4 deals together
Morningside
4 deals together
New Enterprise Associates
4 deals together
ARCH Venture Partners
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Nan Fung Life Sciences invest in?
Nan Fung Life Sciences invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nan Fung Life Sciences?
Public channels for Nan Fung Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nan Fung Life Sciences?
The team at Nan Fung Life Sciences includes Peter Bisgaard (Managing Director), Peter Bisgaard (Managing Director) and Vincent Cheung (Founder, Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
